OBJECTIVE: To evaluate the emerging classes of antihyperglycemic agents that target the incretin pathway, including their therapeutic efficacy and side effect profiles, in order to help identify their place among the treatment options for patients with type 2 diabetes. QUALITY OF EVIDENCE: MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews were searched. Most evidence is level I and II. MAIN MESSAGE: Two classes of incretin agents are currently available: glucagonlike peptide 1 (GLP1) receptor agonists and dipeptidyl peptidase 4 (DPP4) inhibitors, both of which lower hyperglycemia considerably without increasing the risk of hypoglycemia. The GLP1 receptor agonists have a greater effect on patients' glycated hemoglobin A(1c) levels and cause sustained weight loss, whereas the DPP4 inhibitors are weight-neutral. CONCLUSION: The GLP1 and DPP4 incretin agents, promising and versatile antihyperglycemic agents, are finding their way into the therapeutic algorithm for treating type 2 diabetes. They can be used in patients not adequately controlled by metformin monotherapy or as initial therapy in those for whom metformin is contraindicated.
OBJECTIVE: To evaluate the emerging classes of antihyperglycemic agents that target the incretin pathway, including their therapeutic efficacy and side effect profiles, in order to help identify their place among the treatment options for patients with type 2 diabetes. QUALITY OF EVIDENCE: MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews were searched. Most evidence is level I and II. MAIN MESSAGE: Two classes of incretin agents are currently available: glucagonlike peptide 1 (GLP1) receptor agonists and dipeptidyl peptidase 4 (DPP4) inhibitors, both of which lower hyperglycemia considerably without increasing the risk of hypoglycemia. The GLP1 receptor agonists have a greater effect on patients' glycated hemoglobin A(1c) levels and cause sustained weight loss, whereas the DPP4 inhibitors are weight-neutral. CONCLUSION: The GLP1 and DPP4 incretin agents, promising and versatile antihyperglycemic agents, are finding their way into the therapeutic algorithm for treating type 2 diabetes. They can be used in patients not adequately controlled by metformin monotherapy or as initial therapy in those for whom metformin is contraindicated.
Authors: David M Nathan; John B Buse; Mayer B Davidson; Robert J Heine; Rury R Holman; Robert Sherwin; Bernard Zinman Journal: Diabetes Care Date: 2006-08 Impact factor: 19.112
Authors: L Blonde; E J Klein; J Han; B Zhang; S M Mac; T H Poon; K L Taylor; M E Trautmann; D D Kim; D M Kendall Journal: Diabetes Obes Metab Date: 2006-07 Impact factor: 6.577
Authors: Robert J Heine; Luc F Van Gaal; Don Johns; Michael J Mihm; Mario H Widel; Robert G Brodows Journal: Ann Intern Med Date: 2005-10-18 Impact factor: 25.391
Authors: Bernard Zinman; John Gerich; John B Buse; Andrew Lewin; Sherwyn Schwartz; Philip Raskin; Paula M Hale; Milan Zdravkovic; Lawrence Blonde Journal: Diabetes Care Date: 2009-03-16 Impact factor: 17.152
Authors: Gerwyn Morris; Michael Berk; Andre Carvalho; Javier R Caso; Yolanda Sanz; Ken Walder; Michael Maes Journal: Mol Neurobiol Date: 2016-06-27 Impact factor: 5.590
Authors: So Ra Kim; Dae-Hoon Kim; Soo Hyun Park; Young Seok Kim; Chun Hwa Kim; Tae-Young Ha; Jin Yang; Jae-Keol Rhee Journal: J Diabetes Res Date: 2013-12-12 Impact factor: 4.011